Clinical Trial

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-13; most recent amendment 2026-05-30.
Trial Details
NCT Number NCT07228702
Lead Sponsor Vancouver Coastal Health
Conditions Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Enrollment 1 participants
Start Date 2026-01-11
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-03